Compare TMCI & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TMCI | SABS |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.6M | 181.4M |
| IPO Year | 2021 | N/A |
| Metric | TMCI | SABS |
|---|---|---|
| Price | $2.59 | $3.98 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | $6.87 | ★ $9.00 |
| AVG Volume (30 Days) | ★ 777.8K | 315.6K |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $218,879,000.00 | $114,698.00 |
| Revenue This Year | $3.25 | N/A |
| Revenue Next Year | $1.07 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 7.90 | N/A |
| 52 Week Low | $2.44 | $1.00 |
| 52 Week High | $10.79 | $6.60 |
| Indicator | TMCI | SABS |
|---|---|---|
| Relative Strength Index (RSI) | 29.93 | 58.29 |
| Support Level | $2.64 | $3.88 |
| Resistance Level | $2.76 | $4.03 |
| Average True Range (ATR) | 0.20 | 0.26 |
| MACD | 0.09 | -0.02 |
| Stochastic Oscillator | 27.17 | 83.33 |
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers and hospitals.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.